pembro monotherapy for participants with bcg–unresponsive hr nmibc shows anti-tumour activity
Published 1 year ago • 38 plays • Length 6:23Download video MP4
Download video MP3
Similar videos
-
5:08
pembrolizumab shows notable anti-tumour activity for patients with high-risk nmibc
-
4:05
keynote-057: pembrolizumab monotherapy for high-risk nmibc unresponsive to bcg
-
0:27
cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis #bladdercancer #cancer #news
-
4:59
cg0070 combined with pembro shows promising efficacy in patients with nmibc unresponsive to bcg
-
29:46
introduction to adstiladrin | gene therapy for bcg unresponsive nmibc
-
3:04
high-risk, bcg-unresponsive nmibc beyond rc: intravesical and systemic therapies
-
3:17
n-803-bcg combination shows promising results in bcg-unresponsive nmibc
-
2:01
keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc
-
1:56
real-world evaluation of nadofaragene firadenovec in bcg-unresponsive nmibc
-
4:37
keynote-057: outcomes for patients with bcg-unresponsive nmibc who do not respond to pembrolizumab
-
6:04
final results of core-001: cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis
-
11:45
emerging treatments for bcg unresponsive non-muscle invasive bladder cancer
-
2:04
why do bcg-unresponsive patients with nmibc refuse radical cystectomy?
-
25:47
06 bcg failure in high grade nmibc what next prof a zlotta
-
1:55
durvalumab monotherapy for patients with bcg-unresponsive carcinoma-in-situ bladder cancer
-
0:57
keynote-676 cohort a: pembrolizumab plus bcg in recurrent hr nmibc
-
26:33
questions and answers on adstiladrin | gene therapy for bcg unresponsive nmibc
-
1:37
dr. balar on next steps of the keynote-057 trial in nmibc
-
6:49
the evolving landscape in the management of high-risk non-muscle-invasive bladder cancer